Bronchitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Bronchitis - Pipeline Review, H2 2018’, provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchitis

- The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects

- The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Bronchitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bronchitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advanced Inhalation Therapies (AIT) Ltd

AstraZeneca Plc

Daewon Pharm Co Ltd

DBV Technologies SA

F. Hoffmann-La Roche Ltd

Han Wha Pharma Co Ltd

Icure Pharmaceutical ...

Advanced Inhalation Therapies (AIT) Ltd

AstraZeneca Plc

Daewon Pharm Co Ltd

DBV Technologies SA

F. Hoffmann-La Roche Ltd

Han Wha Pharma Co Ltd

Icure Pharmaceutical Inc

Kyorin Pharmaceutical Co Ltd

Merck & Co Inc

Onspira Therapeutics Inc

Orbis Biosciences Inc

Therabron Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchitis – Overview

Bronchitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchitis – Overview

Bronchitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchitis – Companies Involved in Therapeutics Development

Advanced Inhalation Therapies (AIT) Ltd

AstraZeneca Plc

Daewon Pharm Co Ltd

DBV Technologies SA

F. Hoffmann-La Roche Ltd

Han Wha Pharma Co Ltd

Icure Pharmaceutical Inc

Kyorin Pharmaceutical Co Ltd

Merck & Co Inc

Onspira Therapeutics Inc

Orbis Biosciences Inc

Therabron Therapeutics Inc

Bronchitis – Drug Profiles

alteplase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alvelestat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-367 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cyclosporine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DW-1601 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

formoterol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-051 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirfenidone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Antagonize IL1B for Bronchiolitis Obliterans – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNSP-146 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YJP-40 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchitis – Dormant Projects

Bronchitis – Discontinued Products

Bronchitis – Product Development Milestones

Featured News & Press Releases

Apr 26, 2018: AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants

Dec 01, 2017: AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal

Nov 21, 2017: AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017

Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings

Feb 03, 2014: AIT To Present Noxcurebr At The Annual Meeting Of The Israeli Association Of Clinical Pediatrics

Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants

Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine

Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA

Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bronchitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by ...

List of Tables

Number of Products under Development for Bronchitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Bronchitis – Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018

Bronchitis – Pipeline by AstraZeneca Plc, H2 2018

Bronchitis – Pipeline by Daewon Pharm Co Ltd, H2 2018

Bronchitis – Pipeline by DBV Technologies SA, H2 2018

Bronchitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Bronchitis – Pipeline by Han Wha Pharma Co Ltd, H2 2018

Bronchitis – Pipeline by Icure Pharmaceutical Inc, H2 2018

Bronchitis – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Bronchitis – Pipeline by Merck & Co Inc, H2 2018

Bronchitis – Pipeline by Onspira Therapeutics Inc, H2 2018

Bronchitis – Pipeline by Orbis Biosciences Inc, H2 2018

Bronchitis – Pipeline by Therabron Therapeutics Inc, H2 2018

Bronchitis – Dormant Projects, H2 2018

Bronchitis – Dormant Projects, H2 2018 (Contd..1), H2 2018

Bronchitis – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Bronchitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Bronchitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports